Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
10,061
Total Claims
$1.3M
Drug Cost
589
Beneficiaries
$2,123
Cost/Patient
Risk Score Breakdown 6/100
Score components are additive. Read full methodology
Peer Comparison vs. 110,156 Internal Medicine providers
-95%
Opioid rate vs peers
0.1% vs 2.2% avg
+50%
Cost per patient vs peers
$2,123 vs $1,411 avg
+8%
Brand preference vs peers
11.5% vs 10.6% avg
Opioid Prescribing
0.1%
Opioid Rate
11
Opioid Claims
$52
Opioid Cost
—
Long-Acting Rate
Brand vs Generic
Brand: 1,149 claims · $1.1M
Generic: 8,851 claims · $196K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Dapagliflozin Propanediol | 183 | $219K |
| Semaglutide | 104 | $163K |
| Apixaban | 94 | $91K |
| Empagliflozin | 54 | $74K |
| Dulaglutide | 39 | $59K |
| Fluticasone/Umeclidin/Vilanter | 41 | $54K |
| Dapaglifloz Propaned/Metformin | 26 | $38K |
| Rivaroxaban | 20 | $27K |
| Sitagliptin Phos/Metformin Hcl | 13 | $22K |
| Sitagliptin Phos/Metformin Hcl | 12 | $20K |
| Umeclidinium Brm/Vilanterol Tr | 15 | $18K |
| Empagliflozin/Metformin Hcl | 15 | $17K |
| Linagliptin | 14 | $16K |
| Insulin Glargine,hum.Rec.Anlog | 26 | $15K |
| Sitagliptin Phosphate | 12 | $14K |
Prescribing Profile
Patient Profile
75
Avg Age
42%
Female
1.32
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data